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ABSTRACT
Background
Cancer follow-up has traditionally been undertaken in
secondary care, but there are increasing calls to deliver
it in primary care.
Aim
To compare the effectiveness and cost-effectiveness of
primary versus secondary care follow-up of cancer
patients, determine the effectiveness of the integration
of primary care in routine hospital follow-up, and
evaluate the impact of patient-initiated follow-up on
primary care.
Design of study
Systematic review.
Setting
Primary and secondary care settings.
Method
A search was carried out of 19 electronic databases,
online trial registries, conference proceedings, and
bibliographies of included studies. The review included
comparative studies or economic evaluations of
primary versus secondary care follow-up, hospital
follow-up with formal primary care involvement versus
conventional hospital follow-up, and hospital follow-up
versus patient-initiated or minimal follow-up if the
study reported the impact on primary care.
Results
There was no statistically significant difference for
patient wellbeing, recurrence rate, survival, recurrence-
related serious clinical events, diagnostic delay, or
patient satisfaction. GP-led breast cancer follow-up
was cheaper than hospital follow-up. Intensified
primary health care resulted in increased home-care
nurse contact, and improved discharge summary led to
increased GP contact. Evaluation of patient-initiated or
minimal follow-up found no statistically significant
impact on the number of GP consultations or cancer-
related referrals.
Conclusion
Weak evidence suggests that breast cancer follow-up
in primary care is effective. Interventions improving
communication between primary and secondary care
could lead to greater GP involvement. Discontinuation
of formal follow-up may not increase GP workload.
However, the quality of the data in general was poor,
and no firm conclusions can be reached.
Keywords
long-term care; neoplasms; outpatients; primary health
care; systematic review.
INTRODUCTION
Following completion of treatment, most cancer
patients are followed up regularly in hospital
outpatient clinics. The perceived benefit of this is to
facilitate diagnosis of recurrent disease, monitor the
effectiveness and side-effects of treatment, manage
comorbidity, and identify and treat psychosocial
problems.1–4 There is also evidence that patients
value the psychological and social support that
cancer follow-up provides,5–8 and find it reassuring.9–11
Conversely, hospital follow-up might also prompt
unnecessary tests, raise anxiety, provide false
reassurance, and delay the patient’s return to full
function. For some cancer sites, such as breast and
colorectal cancer, there is good evidence that routine
follow-up does not provide survival benefit or lead to
earlier diagnosis of recurrences, other than in terms
of detecting locoregional recurrence or contralateral
new primaries.12–16
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Follow-up of cancer accounts for a substantial
burden of outpatient activity. Financial and other
drivers are putting downward pressure on ‘routine’
secondary care follow-up, and new models of care
are developing, often through cancer collaboratives.17
In the UK, primary care, with its universal system of
patient registration, generalist skills, and high
satisfaction ratings, may be well placed to undertake
some of this work. The UK general medical services
contract encourages the review of cancer patients by
including this within the Quality and Outcomes
Framework. Some low-risk follow-up is already done
in primary care, notably in prostate cancer, and more
is advocated.18–20 However, this seems to be
happening without rigorous evaluation. There is some
disagreement between specialists and GPs about
where care should be delivered, and debate about
patient preference.21
A systematic review was conducted to compare the
effectiveness and cost-effectiveness of primary versus
secondary care follow-up of cancer patients. The study
also evaluated the impact on primary care of
discontinuing formal follow-up or replacing it with
patient-initiated follow-up, as well as interventions
integrating primary and secondary care for cancer
follow-up. Qualitative studies were also included, but
their findings are reported separately.22 (The review also
looked at nurse-led follow-up as indicated in Figure 1,
the findings of which are reported elsewhere.23)
METHOD
The following databases were searched (from
inception to February 2007) using strategies
designed specifically for each database: MEDLINE,
MEDLINE in process, EMBASE, CINAHL,
PsychINFO, AMED, BIOSIS, Index to Scientific and
Technical proceedings, Science Citation Index,
Social Science Citation Index, Cochrane Central
Register of Controlled Trials, Database of Abstracts
of Reviews of Effects, Cochrane Database of
Systematic Reviews, Health Technology Assessment
database, NHS Economic Evaluation database,
System for Information on Grey Literature, British
Nursing Index, Health Management Information
Consortium, National Research Register, and other
trial registries (n = 7) available via the internet. No
language restriction was used.
Each cancer site was searched separately, and full
details of the search strategy are available on request
and described elsewhere (R Lewis et al, unpublished
data, 2007). (An example of the search strategy used
for breast cancer is presented in Appendix 1.)
Additional references were identified through
reviewing the bibliographies of 16 retrieved
systematic reviews and 42 included studies, and
hand searching five conference proceedings.
The search included any type of study or
economic evaluation that compared cancer follow-
up in primary care with that in a secondary setting. It
also included studies that examined any type of
intervention that involved formal primary care input in
How this fits in
Amid increasing debate, cancer follow-up is being shifted to primary care
settings without rigorous evaluation. GP follow-up for breast cancer may be
effective. A more formal involvement of primary care in routine hospital follow-up
could lead to improved communication between primary and secondary care
and more patients using GPs for support. Discontinuation of formal routine
hospital follow-up does not appear to have an impact on primary care workload.
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Systematic Reviews
References identified by
electronic database search
n = 43 861 (2493 NRR)
Relevant publications n = 86 (73 NNR)
Included studies n = 13
Primary vs secondary care
n = 5 (includes 1 economic evaluation; 2 published as abstracts)
n= 1 ongoing study
GP formal involvement n = 3
Patients-initiated FU (with GP outcomes) n = 3
n = 1 ongoing study
(Includes 2 comparative studies [7 publications] with 
qualitative findings)
Potentially relevant publications
ordered for more detailed 
evaluation after scanning the 
titles and abstracts.
Total n = 263:
database search n = 232 (94 NRR),
handsearcha n = 31
Publications evaluating
different models of FU
n = 134
Publications excluded because
they did not meet the inclusion 
criteria for the main reviewb
n = 129
(discussion/commentary;
literature review; uncontrolled
quantitative studies; not 
evaluating cancer care; not 
evaluating cancer care FU;
evaluating effectiveness of 
different tests in FU; evaluating
effectiveness of different FU
intervals; comparative
patient-initiated or
discontinuation of FU studies 
with no GP-related outcomes)
Comparative nurse-led FU 
studies
(reported elsewhere)
n = 20 publications 
n = 9 studies (6 completed
studies plus 3 ongoing)
Qualitative studies reported
separately
n = 28 publications
n = 21 studies (17 studies 
published in full, 2 published
as abstracts only, and 2
unpublished)
aHandsearch of reference lists (16 systematic reviews and 42 included studies), internet searches
(7 trials registries), and conference proceedings (n = 5). bCancer Research UK-funded systematic
review looking at primary versus secondary care follow-up, which also evaluated the impact of
alternative types of follow-up (including nurse-led follow-up) on primary care, and people’s views
of follow-up irrespective of provider. Review of nurse-led follow-up was expanded to include
comparative studies that did not report primary care-related outcomes (such as interim visits to
GP), and is reported elsewhere.23NRR = National Research Register (short abstracts without
results). FU = follow-up.
Figure 1. Flow diagram
showing the number of
references identified,
retrieved, and included in
the review.
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routine hospital follow-up. Any type of outcome
measure was included. Studies that compared
follow-up with no follow-up or patient-initiated
follow-up were also considered, but only if they
reported data on primary care-related outcomes. The
population of interest included patients of any age
who had received treatment for any type and stage
of cancer. Only studies that examined the follow-up
of patients who were free of active disease or no
longer receiving treatment for the following purposes
were included: to identify recurrent tumours of new
primary disease; to provide support for
complications or delayed side-effects of treatments;
or to identify patients who may require additional
help or treatments (for example, for functional or
psychological problems). Studies that examined
patients who were still receiving hospital-based
treatment (for example, radiotherapy) or treatment
after care, rehabilitation, or specialist palliative care
were excluded. Patients in cancer follow-up but
receiving long-term therapy, such as hormonal
treatment for breast or prostate cancer, who did not
require frequent or routine hospital visits and who
were free of active disease were included.
Two reviewers independently assessed the results
of each cancer site-specific literature search and the
relevance of retrieved studies. Data were extracted
by one reviewer, using a predefined form, and
checked by a second independent reviewer. Quality
assessments were conducted independently by two
reviewers. Disagreements were resolved by
discussion and, when necessary, a third reviewer
was consulted.
The quality of effectiveness studies was assessed
using the checklist developed by Downs and Black,24
modified according to the suggestions made by
Deeks et al,25 and adapted for use on cancer follow-
up studies. Economic evaluations were assessed
using an updated version of the checklist developed
by Drummond and Jefferson.26
Due to variation in the way the outcome data were
reported and analysed, a meta-analysis was not
feasible, even for the same outcome measures within
each follow-up group. A narrative synthesis was
therefore conducted.
RESULTS
The electronic searches identified 43 861 references
of which 232 papers were retrieved in full. Thirty-one
additional studies were identified by hand searching
(Figure 1).
Primary versus secondary care
Five studies compared primary versus secondary
care follow-up,3,27–30 but two were only reported in
abstract form (a non-randomised study of patients
who had undergone haematopoietic stem cell
transplantation for malignant haematologic
disorders28 and a randomised controlled trial [RCT] of
patients with cutaneous melanoma29). The three
published RCTs examined follow-up for breast
cancer3,27 and colon cancer30 (Table 1, part a). One of
the breast cancer studies was a non-inferiority trial,27
and the other incorporated a cost analysis.3 Two
studies recruited patients who had recently
completed primary treatment,27,30 and one study
recruited women who were already receiving follow-
up.3 The percentages of eligible participants who
declined to be randomised to primary or secondary
care follow-up were fairly high (33%,3 40%,30 and
55%27), especially for studies that recruited patients
who had just completed treatment.27,30 Only one
study (breast cancer) incorporated a pre-trial
education session of cancer follow-up for GPs, who
were also given a handbook and discharge summary
information.3 In the remaining two studies, GPs were
provided with a brief summary of the current follow-
up guidance.
The three RCTs that examine primary care versus
secondary care follow-up3,2,30 were well conducted
(Table 2, part a). All used an adequate randomisation
method with allocation concealed from patients and
clinicians. An attempt was made to blind those
measuring the main outcomes in all three studies.
The sample size was fairly small in two studies (range
n = 20330 to 2963), and large in the non-inferiority trial
(n = 968).30 The length of follow-up ranged from 18
months30 to a median of 3.5 years.27
There were no statistically significant differences
between the intervention groups in terms of patient
wellbeing (psychological morbidity and quality of
life), recurrence rate, or survival, but this may be due
to lack of statistical power and the short duration of
the studies (Table 3 and Table 4). The non-inferiority
trial found no statistically significant difference
between the groups for the main outcome of
recurrence-related serious clinical events (defined as
spinal cord compression, pathological fracture,
hypercalcaemia, uncontrolled local recurrence,
brachial plexopathy, or poor functional status at the
time of diagnosis of recurrence), and was unable to
demonstrate statistically significant non-inferiority.27
Although the absolute difference between the
intervention groups was small (1.9%), the observed
lower band of the confidence interval (95% CI =
–2.26 to 2.65) crossed the non-inferiority margin of
1.5%. The patient population included women with
early-stage breast cancer (69% had stage I–II
disease) for whom a serious clinical event is a rare
outcome, and in whom the length of follow-up
(median 3.5 or 4.5 years post diagnosis; 31% had
five-year follow-up) may not have been sufficient to
RA Lewis, RD Neal, NH Williams, et al
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measure the serious effects of recurrent disease.
Although patients remained in the trial until death,
assessment for serious clinical outcomes was only
done until a recurrence was detected or the trial
ended.
Only two studies examined patient satisfaction.3,30
One found that satisfaction with breast cancer
follow-up was higher in the GP group (6 of 12 items)
than the hospital group at 9 months (mid trial),3 but
did not report satisfaction at 18-month follow-up
(end of trial). The second study reported no
statistically significant difference between the groups
at 2 years for colon cancer follow-up.30 Two studies
also evaluated resource use.3,30 Hospital doctors and
GPs were found to differ in the type and number of
diagnostic tests ordered,3,30 as well as the length and
frequency of visits.3 A comprehensive cost analysis
(cost year 1994) found that breast cancer follow-up
by the GP was less costly than routine hospital
follow-up, by a mean of £130 per patient (95% CI =
£112 to £149). This was due to a difference in
physician cost and not because of the variation in
diagnostic tests ordered.3
Formal involvement of GP in cancer care
follow-up versus conventional care
Three RCTs examined formal involvement of primary
care in routine hospital follow-up.31–33 No economic
evaluations were identified. All three studies included
patients with cancer originating from multiple sites
(Table 1, part b). The study by Holtedahl et al
examined an intervention that involved patients being
RA Lewis, RD Neal, NH Williams, et al
Part a Part b
Grunfeld Grunfeld Wattchow Holtedahl Johansson Nielsen
et al, 2006,27et al, 1996,3 et al, 2006,30 et al, 2005,31et al, 2001,32et al, 2003,33
breast breast colon multiple multiple site multiple
Downes and Black24 item score (maximum score) cancer cancer cancer site cancer cancer site cancer
Reporting
Is the aim of the study clearly described? (1) 1 1 1 1 1 1
Are the outcomes to be measured clearly described? (1) 1 1 1 1 1 1
Are the characteristics of participants clearly described? (1) 1 1 1 1 1 1
Are the interventions clearly described? (1) 1 1 1 1 1 1
Are the distributions of principal confounders in each group described? (2) 2 2 1 1 1 2
Are the main findings clearly described? (1) 0 1 1 0 1 1
Can the reader calculate estimates of variability in data for the main outcomes? (1) 1 1 1 1 0 0
Have all important adverse effects been reported? (1) 1 1 1 1 1 0
Have the characteristics of participants lost to follow-up been described? (1) 1 1 1 0 1 0
Have confidence intervals or exact significance levels been reported? (1) 1 1 1 0 0 1
External validity
Were those who were asked to participate, representative of their population? (1) 1 1 1 0 0 1
Were those who agreed to participate representative of their population? (1) 0 1 0 0 0 1
Were the staff/setting/facilities representative of those the majority receive? (1) 1 1 1 1 1 1
Internal validity: bias
Was there an attempt to blind those measuring the main outcomes? (1) 1 1 1 1 0 1
If any results were based on ‘data dredging’, was this made clear? (1) 0 1 1 0 0 0
Do analyses adjust for different lengths of follow-up? (1) 0 0 1 1 1 1
Was the length of follow-up adequate? (1) 1 1 1 0 1 1
Were the statistical tests used appropriate? (1) 1 1 1 1 1 0
Was non-compliance reported appropriately? (1) 1 1 1 1 1 1
Were the main outcome measures used valid and reliable? (1) 1 0 1 1 1 1
Internal validity: confounding (selection bias)
Were control and intervention participants recruited from the same population? (1) 1 1 1 1 1 1
Were participants recruited over the same time period? (1) 1 1 1 1 1 1
Were study participants randomised to intervention groups? (2) 2 2 2 2 2 2
Was randomisation concealed from participants and staff until after recruitment? (1) 1 1 1 0 0 0
Was there adjustment for confounding in the analyses? (2) 1 0 1 0 1 0
Were losses to follow-up taken into account? (1) 1 1 1 0 0 1
Power
Has an estimate of clinically important difference been specified? (2) 1 1 1 0 1 0
Is the sample size adequate? (3) 1 1 2 0 2 1
Total score (maximum 34) 26 27 29 17 22 22
Numbers in brackets indicate highest possible score.
Table 2. Quality of included studies comparing primary- versus secondary-care follow-up.
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invited to attend two 30-minute consultations with
their GP: one soon after completing treatment and the
other 6 months later.31 During the consultation,
patients were asked about their wellbeing and their
experience of having cancer (open-ended questions
provided by researchers). Patients were also advised
to contact their GP if they had any cancer-related
queries or problems. In addition, patients received
routine hospital follow-up; the control group received
routine hospital follow-up only.
The study by Johansson et al examined an
intervention that was part of the Support-Care-
Rehabilitation project, which involved individual
patient support in terms of intensified primary health
care, nutritional support, and psychological
support.32 The intervention was implemented as soon
as possible after randomisation, and patients were
referred to a home-care nurse, who contacted the
patient and suggested follow-up contacts during the
period of primary treatment and rehabilitation or
palliative care. GPs of these patients were informed
of the cancer diagnosis and the referral to the home-
care nurse. Intensified primary health care involved
extended information from the specialist clinics (GPs
and home-care nurses received copies of the
medical records each time the patient was
discharged from hospital after a period of inpatient
care or attended outpatient clinic); education (in
diagnostics and treatments of cancer, pain and diet
management, psychosocial support, and palliative
care); and supervision in cancer care for GPs and
home-care nurses. The control included standard
care, which routinely did not include follow-up
contacts made by home-care nurses.
Nielsen et al examined an intervention which
involved the use of discharge letters that followed
predefined guidelines, which were developed for the
study.33 These included details of the investigations,
treatment, and information the patient had received;
described in detail which physical, psychological,
and social problems the patient had or might expect
to get; contained information about what the
oncologist expected the GP to do; and provided
information about the patient’s type of cancer,
treatment plans, and prognosis as well as
information about treatment of common side effects
and pain. The names and phone numbers of the
hospital doctors and nurses who were responsible
for the patient were also attached to the discharge
letters. Patients received both oral and written
information about the information package given to
their GPs, and were advised to contact their GP if
they had any problems they thought could be solved
in this setting. The control group received routine
hospital care, where the GP was rarely informed of
the patient’s cancer diagnosis, and summary
discharge letters did not follow any guidelines.
The interventions were complex and, in two
studies, involved educating GPs32,33 and/or home-
care nurses32 about cancer. The unit of randomisation
was the patient in both of these studies, although a
type of cluster randomisation was used in one.33 In
one study, once a patient from a practice was
randomised, all subsequent patients from the same
practice were automatically assigned to the same
group.33 In the second study patients in the control
group could have a GP (or home-care nurse) who
had received the educational component of the
intervention, or a GP who had not, but this was not
taken into account in the analysis.32 Two studies
included newly diagnosed patients and the
intervention was initiated prior to the follow-up
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Systematic Reviews
Study details Survival Recurrence
Grunfeld et al, 1996.3 Not reported Diagnostic delay: GP n = 22 versus hospital n = 21;
Cancer site: breast. mean difference 1.5 (95% CI = –13 to 22). Assessed at
Length of follow-up: a single date: recurrence rate GP n = 10 (6.8%) versus
18 months. Sample size: hospital n = 16 (10.8%). No comprehensive review at
n = 296; GP n = 148, end of trial to identify missed recurrences
hospital n = 148
Grunfeld et al, 200627 Deaths (all cause): GP 29 (6.0%), versus hospital 30 Recurrence-related serious clinical events: GP
Cancer site: breast. Length (6.2%); difference: 0.18% (95% CI = –2.90 to 3.26) n = 17 (3.5%) versus hospital n = 18 (3.7%); difference:
of follow-up: median 3.5 years. 0.19% (95% CI = –2.26 to 2.65). Recurrence or new
Sample size: n = 968; contralateral breast cancers: GP n = 54 (11.2%) versus
GP n = 483, hospital n = 485 hospital n = 64 (13.2%); difference: 2.02% (95% CI =
–2.13 to 6.16). Comprehensive review at end of trial
found no missed recurrence
Wattchow et al, 200630 Death rates (per 1000 months on trial): GP n = 6.6 Recurrence rate (per 1000 months on trial): GP n = 7.1
Cancer site: colon. Length versus hospital n = 5.4; P = 0.67, Fisher’s exact test. versus hospital 8.0; P = 0.92, Fisher’s exact test.
of follow-up: 24 months. Median survival (months): GP 31 versus hospital 20; Median time to detection (months): GP n = 9.5 versus
Sample size: n = 203; P = 0.69, log rank test hospital 8.0; P = 0.76, log rank test. Recurrence rate
GP n = 97, hospital n = 106 obtained from state-based cancer registries
Table 3. Results of survival and recurrence.
British Journal of General Practice, July 2009
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period, after completing cancer treatment.32,33 The
study by Holtendahl et al included patients with
primary or relapsing cancer who had completed
treatment.31 The percentages of eligible patients
included in the trials were low and ranged from 41%31
to 47%.33
Study quality ranged from poor31 to moderate,32,33
and all three were poorly reported (Table 2, part b). In
the study by Holtedahl et al, patients were
randomised to intervention or control using sealed
envelopes based on a table of random numbers, but
it was not clear when and how envelopes were
allocated; therefore, allocation concealment could not
be assured.31 Although randomisation by Johansson
et al was based on a computer-generated allocation
schedule and was stratified for diagnosis and stage,
allocation concealment was not reported.32 More
patients with advanced breast cancer were
randomised to the intensified primary healthcare
group than the control. A type of cluster
randomisation was used by Nielsen et al.33 Patients in
the intervention group were younger (n = 47, 39%,
aged 18–49 years) than those in the control group (n
= 32, 25%, aged 18–49 years) and more patients in
the intervention group (n = 99, 82%) were treated with
curative intent than in the control group (n = 94, 74%).
Blind data collection and analysis of outcomes
were not reported by Johansson et al.32 Blinding of
outcomes assessment was also not reported by the
remaining two studies. The main outcomes were
based on data from questionnaires completed by the
patient, and it was unclear whether researchers
handling data were blinded to treatment allocation.31,33
Sample size ranged from small (n = 91)31 to moderate
(n = 527).32 Thirteen (14%) patients in the study by
Holtedahl et al had relapsing cancer.31 The length of
follow-up in all three studies was 6 months, although
only 3-month data were reported for most outcomes
from the study by Johansson et al.32
There were no statistically significant differences
between the intervention groups in terms of patient
wellbeing,31,33 or patient satisfaction relating to GP
Study details Number of patient contacts with primary care Frequency of patient contact with primary care
Holtedahl et al, 2005.31 Number of consultations with GP — Frequency of GP consultations — reported by
Cancer site: multiple sites. patient reported: Int 13 (n = 31) versus H 28 GPs: mean number of consultations in the
Length of follow-up: 6 months. (n = 46); (RR 0.69, 95% CI = 0.43 to 1.11) intervention group was 1.68 (ranged 0–8); number of
Sample size: Int n = 41, H n = 50 patients not stated. Data for control group not reported.
Mean number of consultations — patient reported:
Int 1.26 (n = 31; range 1–7 per patient) versus H 1.04
(n = 46; range 1–5 per patient)
Johansson et al, 2001.32 Contact with home-care nurse — patient reported: Contact with home-care nurse — patient reported:
Cancer site: multiple site. Length Int 86 (n = 203) versus H 11 (n = 178); P<0.05, frequency of contact with nurse was greater in the
of follow-up: 6 months since χ2 test (RR 6.86, 95% CI = 3.78 to 12.42) intervention group than control (number of patients
diagnosis. Sample size: Int n = 260, not stated; P<0.001, Mann–Whitney U test)
H n = 250
Nielsen et al, 2003.33 Contact with GP — patient reported: Int 46 (n = 77) —
Cancer site: multiple site. Length versus H 40 (n = 91); P = 0.046, χ2 test
of follow-up: 6 months since (RR 1.36, 95% CI = 1.01 to 1.83)
diagnosis. Sample size: Int n = 121,
H n = 127
Brown et al, 2002.35 Breast-related GP referral (to hospital): PI 4 —
Cancer site: breast. Length versus H 3; (RR 1.38, 95% CI = 0.34 to 5.64)
of follow-up: 12 months.
Sample size: n = 62; PI 30, H 31
(one patient did not return questionnaires)
Gulliford et al, 1997.36 — Total number of GP visits — patient reported (number
Cancer site: breast. Length of visits/patient not reported): PI 53 (4 cancer related)
of follow-up: median 16 months. versus H 53 (7 cancer related)
Sample size: n =193; PI 97, H 96
Kjeldsen et al, 1999.37 — Median number of GP visits — patient reported: data
Cancer site: colorectal. Length on GP visits based on a random sample of 50 patients
of follow-up: not stated. selected from the two intervention groups, PI 4 (n = 24)
Sample size: n = 320; PI 161, versus H 2 (n = 26), P = 0.33, Mann–Whitney U test
H 159. Data based on a subgroup (no visit due to symptom problem)
of 50 patients who were included
in a RCT of frequent versus virtually
no follow-up during 1983–199447
H = routine hospital follow-up group. Int = intervention group. PI = patient-initiated. RCT = randomised controlled trial. RR = relative risk.
Table 5. Results relating to primary care consultations.
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contact, intersectorial cooperation, and patients’
feelings of being left in limbo33 (Table 4). Two studies
found that the intervention was associated with a
statistically significant increase in the contact with
either the GP33 or home-care nurse32 at 6 months
(Table 5). However, the Holtedahl et al study found
that an intervention comprising two pre-arranged
formal consultations with the GP did not result in a
significant increase in additional GP visits at
6 months.31 There was no statistically significant
difference between the intervention groups for
hospital admissions and outpatient visits.32
Effect of hospital-based patient-initiated or
minimal follow-up on primary care
Three RCTs evaluated the effect of patient-initiated
or (virtually) no follow-up on primary care. Two
studies included women with breast cancer, and
patients in the intervention group were advised to
either telephone the nurse,34 or request an immediate
appointment35 if they had any problems. Women
received an annual mammogram in both studies.
One study included patients who had received
treatment for colorectal cancer, and were advised to
see their GP if they had any abdominal pain or
change in bowel habits lasting more than two
weeks.36 The quality ranged from poor35 to good.34,36
There were no important differences between the
groups for the number of GP visits35,36 or cancer-
related GP referrals.34
DISCUSSION
Summary of main findings
There were no statistically significant differences
between primary and secondary care follow-up of
cancer patients (breast or colon) in terms of patient
wellbeing, psychological morbidity, and patient
satisfaction. However, this may be due to the duration
of follow-up and sample size rather than the
interventions being equivalent. The findings did not
demonstrate any harmful effects of GP-led follow-up.
GP-led follow-up for breast cancer was less costly
than routine hospital follow-up, due to a difference in
physician costs (cost year used 1994). Some
interventions that involved improved integration
between primary and secondary care resulted in an
increase in patient contact with primary care. There
were no significant differences between the groups in
terms of patient wellbeing and satisfaction. However,
these findings are based on poorly reported studies
with a short duration of follow-up. The
discontinuation of routine hospital follow-up or
patient-initiated follow-up did not appear to have an
impact on primary care, but this was based on three
small RCTs. Overall, the quality of the data was
generally poor, and no firm conclusions can be made.
Strengths and limitations of the study
A strength of the review was the comprehensive
literature search. However, to make it manageable,
separate searches were carried out of the electronic
databases for each cancer site, and a general search
was not undertaken using the term ‘cancer’ (or
tumour) alone. Although the searches did identify
studies evaluating multiple cancer sites, it is not
possible to be certain that none were missed.
However, database searches were supplemented by
a search of conference proceedings and reference
lists of included studies and other reviews, which
were not narrowed by cancer site.
The review concentrated on the use of primary
care as an alternative setting for cancer follow-up
and did not address any other issues relating to
follow-up.
Because of the small number of relevant studies, it
was not possible to assess for any publication bias.
The inconsistent methods used to analyse and report
most outcome measures meant that no data could
be pooled in a meta-analysis.
There are limitations of the available evidence
relating to primary- versus secondary-care follow-up,
as it is small and only covers two cancer sites: the
breast3,27 and colon.30 Limitations of the included non-
inferiority RCT meant that the evidence for assessing
the equivalence of the primary and secondary care
settings for breast cancer follow-up was lacking.
There is also a paucity of economic evidence on
primary versus secondary care follow-up. Further
evidence relating to the effectiveness and cost-
effectiveness of primary care follow-up may be
provided by an RCT of primary care follow-up for
cutaneous melanoma,29 and an ongoing RCT of
symptomatic follow-up of colorectal cancer in
primary care augmented with monitoring of tumour
markers or intensive imaging in hospital
(http://www.facs.soton.ac.uk/).
The length of follow-up and sample size were
insufficient to measure delayed diagnosis of
recurrences or survival rates, which means that the
impact of various types of follow-up on such
outcomes is not clear. Duration of follow-up is also
likely to affect the outcome of patient satisfaction, as
patients are likely to have a different perspective of
their follow-up needs during the first 2 years after
completing treatment, than later in their cancer
journey.37
The data-collection tools used for psychological
morbidity, health-related quality of life, and patient
satisfaction were limited. Although the Hospital
Anxiety and Depression Scale and Short Form-36 are
good instruments to measure global function, they
are not designed to measure cancer survivor
symptoms. On the whole, patient satisfaction
e243
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questionnaires were not well developed, and the
response rates were poor, making the findings
potentially unreliable.
The patient population evaluated in the
comparative studies may not have been
representative of the population attending cancer
follow-up as a whole, because patients who did not
want primary care follow-up may not have been
randomised.
Comparison with existing literature
Other reviews of cancer follow-up have included
comparisons between different models of follow-up,
providers, and location. Only one other systematic
review looking at primary versus secondary care
follow-up has been identified.38 This review evaluated
RCTs of alternative methods of follow-up in breast
cancer, including reduced frequency of visits. It
included seven RCTs: two that compared primary
with secondary care follow-up,3,27 two that evaluated
nurse-led patient-initiated follow-up,34,39 one that
evaluated nurse-led routine follow-up,40 and two that
examined different frequencies of follow-up.35,41 The
authors concluded that all trials were of inadequate
power or duration to establish the ideal frequency of
appointments or safety of alternative models of
follow-up, but the alternative methods of follow-up
had no detrimental effect on satisfaction or outcome.
Two further reviews evaluating the effectiveness of
breast cancer follow-up found that patient survival
and quality of life were not affected by location of
care.12,14 A systematic review of follow-up for
cutaneous melanoma found no studies that
examined differences between different providers or
locations of follow-up.16
Previous systematic reviews found that the only
effective follow-up procedures in breast cancer were
mammography and physical examination.12,13,42
Systematic reviews of colorectal cancer found that
intensive hospital follow-up led to an overall survival
benefit of about 20% when compared with less-
intensive follow-up.43,44 The survival benefit appeared
to be associated with the measurement of
carcinoembryonic antigen combined with liver
imaging. A systematic review of follow-up for
cutaneous melanoma found no evidence to support
high-intensity follow-up. Only medical history and
physical examination appeared to be cost-effective.16
However, new technological developments in follow-
up methods may change the picture of what to do.
Implications for future research and clinical
practice
With further training for GPs, rapid access to hospital
specialists, and annual mammography, breast
cancer follow-up would be feasible in primary care.
However, further psychosocial studies are needed to
determine its acceptability. The follow-up of of colon
cancer might also be feasible, but the evidence base
is limited. Results of research in progress are awaited
(http://www.facs.soton.ac.uk/). Primary-care follow-
up for breast cancer might also be cost-effective.
However, it is dependent on the unit cost of GP care,
and would require additional funding as it is not a
core activity. The willingness of primary care to
undertake this additional work is unknown, but
interventions that improved communication between
primary and secondary care were found to increase
GP involvement in cancer care.31–33 Poor
communication between primary and secondary
care was seen as a barrier in the current authors’
joint publication of qualitative studies,22 and
improved communication is a key recommendation
of the National Institute for Health and Clinical
Excellence guidelines on breast and colorectal
cancer.45,46 The willingness of GPs to undertake this
role may also be hampered by a perceived lack of
specialist knowledge.22 Only one study of primary
care follow-up (breast cancer) incorporated a pre-
trial education session of cancer follow-up for GPs.3
Continued professional education in oncology will be
needed if this role is to be extended.
Further RCTs are needed of primary versus
secondary care follow-up in cancer where the ideal
hospital-based follow-up is transferable to a primary
care setting. The studies need to be of sufficient size
and duration to ensure that important differences
between the intervention groups are identified. They
should also include robust psychosocial outcome
measures. Future research should include a health-
economic analysis that takes into account the
current cost of general practice and the additional
funding required for this non-core activity.
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Search strategy
The following search strategy for breast cancer was used in MEDLINE (using the OVID interface), and
subsequently translated and adapted for use in other databases (and for other cancer sites).
1. Patient discharge/
2. ((followup$ or follow-up$ or follow up or follow ups) adj4 (discharg$ or discontin$)).ti,ab.
3. ((checkup$ or check-up$ or check up$) adj4 (discharg$ or discontin$)).ti,ab.
4. ((followup$ or follow-up$ or follow up or follow ups) adj4 (stop or stops or stopping or stopped)).ti,ab.
5. ((followup$ or follow-up$ or follow up or follow ups) adj4 (cease or ceases or ceasing or ceased or
cessation)).ti,ab.
6. ((checkup$ or check-up$ or check up or check ups) adj4 (cease or ceases or ceasing or ceased or
cessation)).ti,ab.
7. ((followup$ or follow-up$ or follow up or follow ups) adj4 (end or ends or ending or ended)).ti,ab.
8. ((checkup$ or check-up$ or check up or check ups) adj4 (end or ends or ending or ended)).ti,ab.
9. ((followup$ or follow-up$ or follow up or follow ups) adj4 terminat$).ti,ab.
10.((followup$ or follow-up$ or follow up or follow ups) adj4 finish$).ti,ab.
11.((followup$ or follow-up$ or follow up or follow ups) adj4 withdraw$).ti,ab.
12.((followup$ or follow-up$ or follow up or follow ups) adj4 (cut-off or cut off)).ti,ab.
13.continuity of patient care/
14.((minimal or conventional) adj2 (surveillance$ or followup$ or follow-up$ or follow up or follow ups)).ti,ab.
15.(routine adj2 (followup$ or follow-up$ or follow up or follow ups or visit$)).ti,ab.
16.(routine adj2 (checkup$ or check-up$ or check up or check ups)).ti,ab.
17.(surveillance$ adj2 (recur$ or relaps$ or protocol$ or routine$ or regular$ or followup$ or follow-up$ or follow
up or follow ups)).ti,ab.
18.(surveillance$ adj2 (test or tests or testing or tested or hospital or outpatient$ or out-patient or out patient$
or standard$)).ti,ab.
19.((intensive or frequent or aggressive) adj2 (surveillance$ or followup$ or follow-up$ or follow up or follow
ups)).ti,ab.
20.active$ monitor$.ti,ab.
21.(routine adj2 exam$).ti,ab.
22.(routine adj2 review$).ti,ab.
23.(routine$ adj2 (test or tests or testing or tested)).ti,ab.
24.(outpatient$ adj2 (followup$ or follow-up$ or follow up or follow ups)).ti,ab.
25.(outpatient$ adj2 (checkup$ or check-up$ or check up or check ups)).ti,ab.
26.(systematic adj2 (followup$ or follow-up$ or follow up or follow ups)).ti,ab.
27.(scheduled adj2 (followup$ or follow-up$ or follow up or follow ups)).ti,ab.
28.(scheduled adj2 (checkup$ or check-up$ or check up or check ups)).ti,ab.
29.(regular$ adj2 (followup$ or follow-up$ or follow up or follow ups)).ti,ab.
30.(regular$ adj2 (checkup$ or check-up$ or check up or check ups)).ti,ab.
31.(specialist$ adj2 (followup$ or follow-up$ or follow up or follow ups)).ti,ab.
32.(hospital$ adj2 (followup$ or follow-up$ or follow up or follow ups)).ti,ab.
33.(hospital$ adj2 (checkup$ or check-up$ or check up or check ups)).ti,ab.
34.((clinic or clinics) adj2 (followup$ or follow-up$ or follow up or follow ups)).ti,ab.
... continued
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35.((clinic or clinics) adj2 (checkup$ or check-up$ or check up or check ups)).ti,ab.
36.(initiated adj2 (followup$ or follow-up$ or follow up or follow ups)).ti,ab.
37.(initiated adj2 (checkup$ or check-up$ or check up or check ups)).ti,ab.
38.((general practitioner$ or GP$ or practice or physician) adj2 (followup$ or follow-up$ or follow up or follow
ups)).ti,ab.
39.((general practitioner$ or GP$ or practice or physician) adj2 (checkup$ or check-up$ or check up or check
ups)).ti,ab.
40.((telephone or phone$) adj2 (followup$ or follow-up$ or follow up or follow ups)).ti,ab.
41.((telephone or phone$) adj2 (checkup$ or check-up$ or check up or check ups)).ti,ab.
42.((followup$ or follow-up$ or follow up or follow ups) adj2 (secondary or primary)).ti,ab.
43.((checkup$ or check-up$ or check up or check ups) adj2 (secondary or primary)).ti,ab.
44.(nurse$ adj2 (followup$ or follow-up$ or follow up or follow ups)).ti,ab.
45.(nurse$ adj2 (checkup$ or check-up$ or check up or check ups)).ti,ab.
46.(standard$ adj2 (followup$ or follow-up$ or follow up or follow ups)).ti,ab.
47.(standard$ adj2 (checkup$ or check-up$ or check up or check ups)).ti,ab.
48.((followup$ or follow-up$ or follow up or follow ups) adj2 regime$).ti,ab.
49.((followup$ or follow-up$ or follow up or follow ups) adj2 (postsurgery or post-surgery or post surgery or
postsurgical$ or post-surgical$ or post surgical$ or postoperat$ or post-operat$ or post operat$)).ti,ab.
50.((checkup$ or check-up$ or check up or check ups) adj2 (postsurgery or post-surgery or post surgery or
postsurgical$ or post-surgical$ or post surgical$ or postoperat$ or post-operat$ or post operat$)).ti,ab.
51.((followup$ or follow-up$ or follow up or follow ups) adj2 appointment$).ti,ab.
52.((checkup$ or check-up$ or check up or check ups) adj2 appointment$).ti,ab.
53.or/1–52
54.exp Breast Neoplasms/
55.((breast or breasts or mammar$) adj3 (cancer$ or neoplas$ or malignan$ or carcinoma$ or sarcoma$ or
oncolog$ or tumo?r$ or adenocarcinoma$ or infiltrat$ or medullary or intraductal)).ti,ab.
56.((breast or breasts or mammar$) adj3 (duct or ducts or ductal)).ti,ab.
57.((breast or breasts or mammar$) adj3 (lobule$ or lobe or lobes or lobular)).ti,ab.
58.((breast or breasts or mammar$) adj3 (metastas$ or metastatic$)).ti,ab.
59.54 or 55 or 56 or 57 or 58
60.53 and 59
The strategy is based on the one used for an unpublished scoping review (looking at follow-up for breast cancer) undertaken by
the Centre for Reviews and Dissemination, University of York as part of a project with the National Cancer Research Network
Coordinating Centre.
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